ATLAS / Macro Radar / Reporting / OLMA

Olema Pharmaceuticals, Inc. (OLMA) reporting calendar

Olema Pharmaceuticals, Inc. files periodic reports with the SEC as OLMA on Nasdaq. Atlas tracks 22 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
22 Jul 2026 – 31 Aug 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
12 May 2026
Reports on record
22

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 42 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 202612 May 202642 days0001193125-26-218156
10-K31 Dec 202516 Mar 202675 days0001193125-26-107169
10-Q30 Sep 202510 Nov 202541 days0001193125-25-273236
10-Q30 Jun 202511 Aug 202542 days0000950170-25-106565
10-Q31 Mar 202513 May 202543 days0000950170-25-070374
10-K31 Dec 202418 Mar 202577 days0000950170-25-041204
10-Q30 Sep 202412 Nov 202443 days0000950170-24-125427
10-Q30 Jun 20246 Aug 202437 days0000950170-24-091836
10-Q31 Mar 20248 May 202438 days0000950170-24-055686
10-K31 Dec 202311 Mar 202471 days0000950170-24-029281
10-Q30 Sep 20237 Nov 202338 days0001558370-23-017994
10-Q30 Jun 20238 Aug 202339 days0001558370-23-013936
10-Q31 Mar 20239 May 202339 days0001558370-23-008815
10-K31 Dec 20229 Mar 202368 days0001558370-23-003318
10-Q30 Sep 20228 Nov 202239 days0001558370-22-016903
10-Q30 Jun 20229 Aug 202240 days0001558370-22-012930
10-Q31 Mar 20229 May 202239 days0001558370-22-007860
10-K31 Dec 202128 Feb 202259 days0001558370-22-002388
10-Q30 Sep 202110 Nov 202141 days0001558370-21-015506
10-Q30 Jun 202110 Aug 202141 days0001558370-21-011141
10-Q31 Mar 202111 May 202141 days0001558370-21-006823
10-K31 Dec 202017 Mar 202176 days0001558370-21-003141

Source: SEC EDGAR company submissions for CIK 0001750284. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.